Literature DB >> 15473997

Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice.

Donna L Herber1, Lisa M Roth, David Wilson, Nedda Wilson, Jerimiah E Mason, Dave Morgan, Marcia N Gordon.   

Abstract

Inflammation has been argued to play a primary role in the pathogenesis of Alzheimer's disease (AD). Lipopolysaccharide (LPS) activates the innate immune system, triggering gliosis and inflammation when injected in the central nervous system. In studies described here, APP transgenic mice were injected intrahippocampally with 4 or 10 microg of LPS and evaluated 1, 3, 7, 14, or 28 days later. Abeta load was significantly reduced at 3, 7, and 14 days but surprisingly returned near baseline 28 days after the injection. No effects of LPS on congophilic amyloid deposits could be detected. LPS also activated both microglia and astrocytes in a time-dependent manner. The GFAP astrocyte reaction and the Fcgamma receptor microglial reaction peaked at 7 days after LPS injection, returning to baseline by 2 weeks postinjection. When stained for CD45, microglial activation was detected at all time points, although the morphology of these cells transitioned from an ameboid to a ramified and bushy appearance between 7 and 14 days postinjection. These results indicate that activation of brain glia can rapidly and transiently clear diffuse Abeta deposits but has no effect on compacted fibrillar amyloid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15473997     DOI: 10.1016/j.expneurol.2004.07.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  77 in total

Review 1.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Future Neurol       Date:  2012-03-01

3.  The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.

Authors:  Henri J Huttunen; Daniel Havas; Camilla Peach; Cory Barren; Stephan Duller; Weiming Xia; Matthew P Frosch; Birgit Hutter-Paier; Manfred Windisch; Dora M Kovacs
Journal:  J Neuropathol Exp Neurol       Date:  2010-08       Impact factor: 3.685

Review 4.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease.

Authors:  Kurt M Lucin; Caitlin E O'Brien; Gregor Bieri; Eva Czirr; Kira I Mosher; Rachelle J Abbey; Diego F Mastroeni; Joseph Rogers; Brian Spencer; Eliezer Masliah; Tony Wyss-Coray
Journal:  Neuron       Date:  2013-09-04       Impact factor: 17.173

Review 6.  Immune activation in brain aging and neurodegeneration: too much or too little?

Authors:  Kurt M Lucin; Tony Wyss-Coray
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

7.  Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.

Authors:  Jean-Philippe Michaud; Maxime Hallé; Antoine Lampron; Peter Thériault; Paul Préfontaine; Mohammed Filali; Pascale Tribout-Jover; Anne-Marie Lanteigne; Rachel Jodoin; Christopher Cluff; Vincent Brichard; Rémi Palmantier; Anthony Pilorget; Daniel Larocque; Serge Rivest
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-15       Impact factor: 11.205

Review 8.  Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  Clive Holmes; Darren Cotterell
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 9.  Inflammation, microglia, and Alzheimer's disease.

Authors:  Brent Cameron; Gary E Landreth
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

10.  Staging anti-inflammatory therapy in Alzheimer's disease.

Authors:  Mathieu P Lichtenstein; Paulina Carriba; Roser Masgrau; Aurora Pujol; Elena Galea
Journal:  Front Aging Neurosci       Date:  2010-10-25       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.